The phase 3 PANORAMA 1 trial previously demonstrated that panobinostat plus bortezomib and dexamethasone significantly prolonged progression-free survival vs bortezomib and dexamethasone alone. Final overall survival analysis is presented.
Adding daratumumab to lenalidomide and dexamethasone significantly prolonged progression-free survival compared with lenalidomide plus dexamethasone alone in patients with relapsed or refractory multiple myeloma.
The combination of ixazomib and dexamethasone is clinically active and well tolerated in patients with relapsed multiple myeloma not refractory to bortezomib.
A longer duration of lenalidomide maintenance therapy after autologous HSCT may improve progression-free and overall survival in patients with multiple myeloma.
Antibacterial prophylaxis with the flouroquinolone, ciprofloxacin, substantially reduced the risk of bacteremia and neutropenic fever in patients with multiple myeloma or lymphoma undergoing high-dose chemotherapy and auto-HSCT.
Minimal residual disease (MRD) negativity after treatment is associated with prolonged overall survival in patients with newly diagnosed multiple myeloma.
Researchers have determined the risk of infection for immunomodulatory drug-based therapy and proteasome inhibitor-based therapy with respect to treatment phase in patients with multiple myeloma.
Daratumumab plus bortezomib and dexamethasone improves progression-free survival in multiple myeloma.
Daratumumab plus lenalidomide and dexamethasone resulted in rapid, deep, durable responses in patients with multiple myeloma.
Sociodemographic factors, not race or ethnicity, impact survival of younger patients with multiple myeloma.
Addition of Elotuzumab to Bortezomib/Dexamethasone Improves Survival in Relapsed/Refractory Multiple MyelomaAugust 16, 2016
The addition of elotuzumab to bortezomib/dexamethasone appears to increase progression-free survival in relapsed/refractory multiple myeloma (RRMM).
A family history of lymphoproliferative disorders is not a risk factor for progression from monoclonal gammopathy of undetermined significance (MGUS) to multiple myeloma.
Treatment with daratumumab, lenalidomide, and dexamethasone (DRd) may be superior to lenalidomide and dexamethasone (Rd) alone in patients with relapsed or refractory multiple myeloma.
Increasing body mass index (BMI) allows growth and progression of disease in patients with multiple myeloma, a recently published study has shown.
[Blood and Lymphatic Cancer: Targets and Therapy] This research reviews clinical symptoms, diagnosis, and risk factors of peripheral neuropathy, particularly dealing with the incidence, mechanisms, and management of TiPN and BiPN.
Researchers discovered that changes in the bone marrow needed for multiple myeloma to grow have already taken hold in patients with MGUS.
Assessment and Monitoring of Patients Receiving Chemotherapy for Multiple Myeloma: Strategies to Improve OutcomesJuly 01, 2016
[Blood and Lymphatic Cancer: Targets and Therapy] This research reviews updates in the diagnosis and management of multiple myeloma, and provides for assessment and monitoring strategies for patients receiving chemotherapy for multiple myeloma.
Response to the human CD38-directed monoclonal antibody daratumumab is significantly associated with CD38 expression on the tumor cells in patients with multiple myeloma, per a recent study.
Daratumumab in Combination With Standard-of-Care Treatment Significantly Improves Outcomes in Patients With Multiple MyelomaJune 15, 2016
Daratumumab in combination with the standard-of-care treatment regimen reduced risk of disease progression or death by 63% compared with the standard-of-care regimen alone in patients with multiple myeloma who had received at least 1 prior line of therapy.
A post-hoc analysis of the Phase 3 ASPIRE study indicates that treatment combining carfilzomib with lenalidomide and dexamethasone extended survival time for patients with multiple myeloma.
A third clinical trial is beginning for phase I testing of SurVaxM, a cancer vaccine. This trial tests for safety and effectiveness of the vaccine in combination with lenalidomide as maintenance therapy for adults with multiple myeloma.
Daratumumab + Bortezomib/Dexamethasone: Reduced Risk of Disease Progression Seen in Relapsed or Refractory Multiple MyelomaJune 06, 2016
Adding daratumumab to bortezomib and dexamethasone was associated with a 61% reduction in risk of disease progression in patients with relapsed or refractory multiple myeloma (RRMM), according to results of the phase 3 CASTOR study presented in a plenary session at the ASCO 2016 Annual Meeting.
Lenalidomide maintenance after high-dose melphalan and autologous stem cell transplant (ASCT) significantly prolonged overall survival in patients with multiple myeloma compared with no maintenance, a meta-analysis of 3 randomized controlled trials presented at the 2016 ASCO Annual Meeting has found.
Upfront autologous stem cell transplantation (ASCT) remains the preferred treatment for patients age 65 years or younger with newly diagnosed multiple myeloma, according to phase 3 study results reported at the 2016 ASCO Annual Meeting.
Progression-free-survival was improved in all prespecified patient groups, including those with high-risk cytogenetic abnormalities.
Cancer stem cells that drive tumor growth were halved by MEDI-551, an experimental antibody treatment for multiple myeloma, according to results of a small preliminary clinical trial.
The addition of elotuzumab to bortezomib and dexamethasone prolongs progression-free survival without worsening clinical toxicity in patients with relapsed/refractory multiple myeloma.
Sexual problems appear to be a prominent, and largely unaddressed issue for patients with myeloproliferative neoplasms.
Costs of care for elderly patients with myelodysplastic syndromes (MDS) enrolled in Medicare are not associated with survival.
What is the new drug called Empliciti and how does it differ from other drugs used to treat multiple myeloma?
- Novel Colonoscopy Prep Is Poised to Improve Screening Rates for Colon Cancer
- PPIs Negatively Impact Outcomes of Patients Treated With Capecitabine
- How Physical Changes From Breast Cancer Affect Self-Image: Considerations for Clinicians
- Panobinostat Modestly Improves OS in Relapsed Multiple Myeloma
- Short-Term Intervention May Have Long-term Diet Effect in Hispanic Breast Cancer Survivors
- Overall Benefits of Vaporized Nicotine Products Outweigh Harms, Says International Panel of Experts
- Sugar and Cancer: Mitigating the Affects of Diet on Cancer
- Nurse Residency Programs Can Impact Oncology Nursing Practice, Outcomes
- Implementing a Distress Screening Process for Cancer Patients
- Initiating Palliative Care in the Emergency Department
- New Research Identifies Potential Bladder Cancer Chemotherapy Side Effect
- Pseudohyperkalemia: False Potassium Levels Occur in a Patient With Lymphoma
- Atezolizumab Granted FDA Approval for Specific Cases of NSCLC
- Low-Dose Sublingual Fentanyl Safe, Effective in Patients Receiving Lower Opioid Doses
- High U.S. Economic Burden for Vaccine-Preventable Diseases
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|